$CVS
CVS Health Corp

2023 Q4 Form 10-Q Financial Statement

#000006480323000047 Filed on November 01, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $93.81B $89.76B
YoY Change 11.89% 10.6%
Cost Of Revenue $79.94B $54.69B
YoY Change 54.53% 8.58%
Gross Profit $13.88B $35.08B
YoY Change -56.8% 13.91%
Gross Profit Margin 14.79% 39.08%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $10.02B $9.876B
YoY Change -64.72% -63.46%
Operating Profit $3.860B $3.690B
YoY Change 3.51% -193.87%
Interest Expense -$690.0M $693.0M
YoY Change 25.0% 22.44%
% of Operating Profit -17.88% 18.78%
Other Income/Expense, Net $22.00M $22.00M
YoY Change -48.84% -46.34%
Pretax Income $2.705B $3.019B
YoY Change -12.99% -167.75%
Income Tax $658.0M $754.0M
% Of Pretax Income 24.33% 24.98%
Net Earnings $2.046B $2.261B
YoY Change -11.12% -166.19%
Net Earnings / Revenue 2.18% 2.52%
Basic Earnings Per Share $1.76
Diluted Earnings Per Share $1.58 $1.75
COMMON SHARES
Basic Shares Outstanding 1.287B shares 1.284B shares
Diluted Shares Outstanding 1.290B shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.46B $16.19B
YoY Change -27.14% -19.02%
Cash & Equivalents $8.196B $13.04B
Short-Term Investments $3.259B $3.145B
Other Short-Term Assets $3.151B $3.074B
YoY Change 17.36% 24.0%
Inventory $18.03B $17.95B
Prepaid Expenses
Receivables $35.23B $32.93B
Other Receivables $3.894B $2.603B
Total Short-Term Assets $67.86B $70.14B
YoY Change 3.31% 2.64%
LONG-TERM ASSETS
Property, Plant & Equipment $30.44B $13.02B
YoY Change 136.43% 3.14%
Goodwill $91.27B $91.26B
YoY Change 16.79% 16.87%
Intangibles $29.23B $29.62B
YoY Change 18.1% 17.76%
Long-Term Investments $23.02B $21.67B
YoY Change 9.12% 5.36%
Other Assets $4.660B $4.825B
YoY Change 0.87% -0.49%
Total Long-Term Assets $181.9B $181.2B
YoY Change 11.86% 11.23%
TOTAL ASSETS
Total Short-Term Assets $67.86B $70.14B
Total Long-Term Assets $181.9B $181.2B
Total Assets $249.7B $251.3B
YoY Change 9.4% 8.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $49.82B $48.92B
YoY Change 11.54% 12.63%
Accrued Expenses $22.19B $22.57B
YoY Change 18.37% 16.21%
Deferred Revenue $149.0M $167.0M
YoY Change 109.86% 125.68%
Short-Term Debt $200.0M $0.00
YoY Change
Long-Term Debt Due $2.772B $2.132B
YoY Change 55.91% 56.42%
Total Short-Term Liabilities $79.19B $81.55B
YoY Change 13.56% 12.63%
LONG-TERM LIABILITIES
Long-Term Debt $58.64B $59.78B
YoY Change 16.17% 17.57%
Other Long-Term Liabilities $6.211B $6.237B
YoY Change -7.74% -7.86%
Total Long-Term Liabilities $6.211B $6.237B
YoY Change -7.74% -7.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $79.19B $81.55B
Total Long-Term Liabilities $6.211B $6.237B
Total Liabilities $173.1B $176.8B
YoY Change 10.28% 10.36%
SHAREHOLDERS EQUITY
Retained Earnings $61.60B $60.34B
YoY Change 9.72% 10.58%
Common Stock $18.00M $18.00M
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $76.46B $74.34B
YoY Change
Total Liabilities & Shareholders Equity $249.7B $251.3B
YoY Change 9.4% 8.69%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income $2.046B $2.261B
YoY Change -11.12% -166.19%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.636B $2.716B
YoY Change 35.04% -70.23%
INVESTING ACTIVITIES
Capital Expenditures $911.0M $545.0M
YoY Change 32.41% -193.97%
Acquisitions
YoY Change
Other Investing Activities -$331.0M -$226.0M
YoY Change -158.17% 0.44%
Cash From Investing Activities -$1.242B -$771.0M
YoY Change 943.7% -4.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -972.0M -2.697B
YoY Change -55.56% -16.19%
NET CHANGE
Cash From Operating Activities -2.636B 2.716B
Cash From Investing Activities -1.242B -771.0M
Cash From Financing Activities -972.0M -2.697B
Net Change In Cash -4.850B -752.0M
YoY Change 13.9% -114.75%
FREE CASH FLOW
Cash From Operating Activities -$2.636B $2.716B
Capital Expenditures $911.0M $545.0M
Free Cash Flow -$3.547B $2.171B
YoY Change 34.36% -77.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
52814000000 usd
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
507000000 usd
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0 usd
CY2022Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-5220000000 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-5704000000 usd
us-gaap Interest Expense
InterestExpense
1735000000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2686000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2147000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
691000000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-3399000000 usd
us-gaap Profit Loss
ProfitLoss
6321000000 usd
us-gaap Profit Loss
ProfitLoss
1995000000 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
4000000 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
7000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
23000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
18000000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
2261000000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3406000000 usd
us-gaap Net Income Loss
NetIncomeLoss
6298000000 usd
us-gaap Net Income Loss
NetIncomeLoss
1977000000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.76
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.90
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.51
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.75
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.49
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1287000000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1315000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1284000000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1315000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1289000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1324000000 shares
CY2023Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.605
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.815
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.65
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-3399000000 usd
us-gaap Profit Loss
ProfitLoss
6321000000 usd
us-gaap Profit Loss
ProfitLoss
1995000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-321000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-637000000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
85000000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-2634000000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-4000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
8000000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
9000000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
20000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
0 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-1000000 usd
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-2000000 usd
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1758000000 shares
CY2021 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201812Member
CY2022Q4 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations
CY2023Q3 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations
CY2023Q3 cvs Operating Expenses Excluding Goodwill Impairments Loss On Assets Held For Sale And Loss On Litigation Settlement
OperatingExpensesExcludingGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement
9876000000 usd
CY2022Q3 cvs Operating Expenses Excluding Goodwill Impairments Loss On Assets Held For Sale And Loss On Litigation Settlement
OperatingExpensesExcludingGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement
9612000000 usd
cvs Operating Expenses Excluding Goodwill Impairments Loss On Assets Held For Sale And Loss On Litigation Settlement
OperatingExpensesExcludingGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement
29329000000 usd
cvs Operating Expenses Excluding Goodwill Impairments Loss On Assets Held For Sale And Loss On Litigation Settlement
OperatingExpensesExcludingGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement
28123000000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
86074000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
4295000000 usd
us-gaap Interest Expense
InterestExpense
1968000000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1313000000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1290000000 shares
CY2022Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.55
CY2023Q3 us-gaap Profit Loss
ProfitLoss
2265000000 usd
CY2023Q3 us-gaap Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax
OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax
181000000 usd
CY2022Q3 us-gaap Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax
OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax
250000000 usd
us-gaap Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax
OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax
167000000 usd
us-gaap Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax
OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax
929000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-7000000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-146000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-385000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
260000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1688000000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
2119000000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-3784000000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
6581000000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
307000000 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
4000000 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
7000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
23000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
18000000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2115000000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3791000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6558000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
289000000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13043000000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12945000000 usd
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
3145000000 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
2778000000 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32927000000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
27276000000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
17954000000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
19090000000 usd
CY2023Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
0 usd
CY2022Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
908000000 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
3074000000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2636000000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
70143000000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
65633000000 usd
CY2023Q3 us-gaap Long Term Investments
LongTermInvestments
21667000000 usd
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
21096000000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13022000000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12873000000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17564000000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17872000000 usd
CY2023Q3 us-gaap Goodwill
Goodwill
91261000000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
78150000000 usd
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
29624000000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
24803000000 usd
CY2023Q3 us-gaap Separate Account Assets
SeparateAccountAssets
3200000000 usd
CY2022Q4 us-gaap Separate Account Assets
SeparateAccountAssets
3228000000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4825000000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4620000000 usd
CY2023Q3 us-gaap Assets
Assets
251306000000 usd
CY2022Q4 us-gaap Assets
Assets
228275000000 usd
CY2023Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
14874000000 usd
CY2022Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
14838000000 usd
CY2023Q3 cvs Pharmacy Claims And Discounts Payable Current
PharmacyClaimsAndDiscountsPayableCurrent
21497000000 usd
CY2022Q4 cvs Pharmacy Claims And Discounts Payable Current
PharmacyClaimsAndDiscountsPayableCurrent
19423000000 usd
CY2023Q3 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
12550000000 usd
CY2022Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
10142000000 usd
CY2023Q3 us-gaap Other Policyholder Funds
OtherPolicyholderFunds
1440000000 usd
CY2022Q4 us-gaap Other Policyholder Funds
OtherPolicyholderFunds
1500000000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22571000000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18745000000 usd
CY2023Q3 cvs Other Insurance Liabilities Current
OtherInsuranceLiabilitiesCurrent
4748000000 usd
CY2022Q4 cvs Other Insurance Liabilities Current
OtherInsuranceLiabilitiesCurrent
1089000000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1741000000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1678000000 usd
CY2023Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
2132000000 usd
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1778000000 usd
CY2023Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
0 usd
CY2022Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
228000000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
81553000000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
69421000000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16441000000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16800000000 usd
CY2023Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
59782000000 usd
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
50476000000 usd
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4250000000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4016000000 usd
CY2023Q3 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3200000000 usd
CY2022Q4 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3228000000 usd
CY2023Q3 cvs Other Insurance Liabilities Noncurrent
OtherInsuranceLiabilitiesNoncurrent
5333000000 usd
CY2022Q4 cvs Other Insurance Liabilities Noncurrent
OtherInsuranceLiabilitiesNoncurrent
5835000000 usd
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6237000000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6730000000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
176796000000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
156506000000 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3200000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3200000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1767000000 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1287000000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1300000000 shares
CY2023Q3 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
48829000000 usd
CY2022Q4 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
48193000000 usd
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
480000000 shares
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
458000000 shares
CY2023Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
33831000000 usd
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
31858000000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
60343000000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
56398000000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1004000000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1264000000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
74337000000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
71469000000 usd
CY2023Q3 us-gaap Minority Interest
MinorityInterest
173000000 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
300000000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
74510000000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71769000000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
251306000000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
228275000000 usd
us-gaap Proceeds From Customers
ProceedsFromCustomers
260300000000 usd
us-gaap Proceeds From Customers
ProceedsFromCustomers
235395000000 usd
cvs Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies
PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies
153051000000 usd
cvs Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies
PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies
138785000000 usd
cvs Payments For Insurance Benefits
PaymentsForInsuranceBenefits
61658000000 usd
cvs Payments For Insurance Benefits
PaymentsForInsuranceBenefits
51434000000 usd
us-gaap Payments To Suppliers And Employees
PaymentsToSuppliersAndEmployees
26038000000 usd
us-gaap Payments To Suppliers And Employees
PaymentsToSuppliersAndEmployees
22728000000 usd
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
1174000000 usd
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
687000000 usd
us-gaap Interest Paid Net
InterestPaidNet
2049000000 usd
us-gaap Interest Paid Net
InterestPaidNet
1936000000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2616000000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3070000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
16062000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
18129000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5547000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5535000000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
6625000000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
6439000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2120000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2039000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
16492000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
131000000 usd
us-gaap Cash Divested From Deconsolidation
CashDivestedFromDeconsolidation
2808000000 usd
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
0 usd
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
-1928000000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-43000000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-74000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4928000000 usd
us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
5000000000 usd
us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
0 usd
us-gaap Repayments Of Other Short Term Debt
RepaymentsOfOtherShortTermDebt
5000000000 usd
us-gaap Repayments Of Other Short Term Debt
RepaymentsOfOtherShortTermDebt
0 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
10898000000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2734000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4195000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2013000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2000000000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
2353000000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
2188000000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
242000000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
510000000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
175000000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
337000000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-210000000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-119000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3655000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8329000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
70000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4872000000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13305000000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12691000000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13375000000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17563000000 usd
us-gaap Profit Loss
ProfitLoss
6321000000 usd
us-gaap Profit Loss
ProfitLoss
1995000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3232000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3181000000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
349000000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
2521000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
461000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
341000000 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
225000000 usd
cvs Deferred Income Taxes And Other Noncash Items
DeferredIncomeTaxesAndOtherNoncashItems
-360000000 usd
cvs Deferred Income Taxes And Other Noncash Items
DeferredIncomeTaxesAndOtherNoncashItems
-2213000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3920000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2009000000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1305000000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
415000000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
518000000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
244000000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2466000000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3350000000 usd
us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
4679000000 usd
us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
4476000000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
2047000000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
7371000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
16062000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
18129000000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71769000000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
2142000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
389000000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
122000000 usd
CY2023Q1 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
1962000000 usd
CY2023Q1 us-gaap Dividends Common Stock
DividendsCommonStock
781000000 usd
CY2023Q1 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
-99000000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71580000000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
1914000000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
17000000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
345000000 usd
CY2023Q2 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
129000000 usd
CY2023Q2 us-gaap Dividends Common Stock
DividendsCommonStock
786000000 usd
CY2023Q2 us-gaap Noncontrolling Interest Increase From Business Combination
NoncontrollingInterestIncreaseFromBusinessCombination
66000000 usd
CY2023Q2 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
-5000000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
73002000000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
2265000000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-146000000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
165000000 usd
CY2023Q3 cvs Espp Issuance Net Of Treasury Stock Value Acquired Cost Method
ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
105000000 usd
CY2023Q3 us-gaap Dividends Common Stock
DividendsCommonStock
786000000 usd
CY2023Q3 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
-95000000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
74510000000 usd
CY2023Q1 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2023Q2 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2022Q4 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2023Q3 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2022Q4 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2023Q2 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2023Q3 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2023Q1 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
75381000000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
2355000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-763000000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
300000000 usd
CY2022Q1 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
1972000000 usd
CY2022Q1 us-gaap Dividends Common Stock
DividendsCommonStock
730000000 usd
CY2022Q1 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
3000000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
74034000000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
3039000000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-540000000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
197000000 usd
CY2022Q2 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
267000000 usd
CY2022Q2 us-gaap Dividends Common Stock
DividendsCommonStock
729000000 usd
CY2022Q2 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
2000000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
75736000000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-3399000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-385000000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
173000000 usd
CY2022Q3 cvs Espp Issuance Net Of Treasury Stock Value Acquired Cost Method
ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
86000000 usd
CY2022Q3 us-gaap Dividends Common Stock
DividendsCommonStock
723000000 usd
CY2022Q3 cvs Noncontrolling Interest Other Period Increase Decrease
NoncontrollingInterestOtherPeriodIncreaseDecrease
-1000000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71487000000 usd
CY2021Q4 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2022Q3 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2022Q2 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2022Q1 cvs Treasury Stock Shares Held In Trust
TreasuryStockSharesHeldInTrust
1000000 shares
CY2022Q3 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2022Q1 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2021Q4 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2022Q2 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
18000000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
17000000 usd
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
17000000 usd
CY2023Q3 cvs Number Of Pharmacy Plan Members
NumberOfPharmacyPlanMembers
110000000 people
CY2023Q3 cvs Number Of Patients Served Per Year
NumberOfPatientsServedPerYear
1000000 patient
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 segment
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform with the current year presentation.</span></div>
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13043000000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12945000000 usd
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
96000000 usd
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
144000000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
236000000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
216000000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13375000000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13305000000 usd
CY2023Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
10424000000 usd
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
8983000000 usd
CY2023Q3 cvs Vendor And Manufacturer Receivables
VendorAndManufacturerReceivables
16646000000 usd
CY2022Q4 cvs Vendor And Manufacturer Receivables
VendorAndManufacturerReceivables
12395000000 usd
CY2023Q3 us-gaap Premiums Receivable At Carrying Value
PremiumsReceivableAtCarryingValue
3254000000 usd
CY2022Q4 us-gaap Premiums Receivable At Carrying Value
PremiumsReceivableAtCarryingValue
2676000000 usd
CY2023Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2603000000 usd
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
3449000000 usd
CY2023Q3 cvs Accounts Receivable After Allowance For Credit Loss Current Including Assets Held For Sale
AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale
32927000000 usd
CY2022Q4 cvs Accounts Receivable After Allowance For Credit Loss Current Including Assets Held For Sale
AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale
27503000000 usd
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
357000000 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
333000000 usd
CY2022Q4 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
1219000000 usd
CY2021Q4 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
879000000 usd
us-gaap Deferred Policy Acquisition Costs Additions
DeferredPolicyAcquisitionCostsAdditions
414000000 usd
us-gaap Deferred Policy Acquisition Costs Additions
DeferredPolicyAcquisitionCostsAdditions
423000000 usd
us-gaap Deferred Policy Acquisition Cost Amortization Expense
DeferredPolicyAcquisitionCostAmortizationExpense
196000000 usd
us-gaap Deferred Policy Acquisition Cost Amortization Expense
DeferredPolicyAcquisitionCostAmortizationExpense
163000000 usd
CY2023Q3 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
1437000000 usd
CY2022Q3 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
1139000000 usd
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2023Q3 us-gaap Net Investment Income
NetInvestmentIncome
277000000 usd
CY2023Q3 us-gaap Revenues
Revenues
89764000000 usd
CY2022Q3 us-gaap Net Investment Income
NetInvestmentIncome
201000000 usd
CY2022Q3 us-gaap Revenues
Revenues
81159000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
885000000 usd
us-gaap Revenues
Revenues
263963000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
515000000 usd
us-gaap Revenues
Revenues
238621000000 usd
CY2023Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
10424000000 usd
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
8983000000 usd
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
167000000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
71000000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
71000000 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
87000000 usd
cvs Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance
ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance
250000000 usd
cvs Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance
ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance
250000000 usd
cvs Contract With Customer Liability Redemption And Breakage
ContractWithCustomerLiabilityRedemptionAndBreakage
267000000 usd
cvs Contract With Customer Liability Redemption And Breakage
ContractWithCustomerLiabilityRedemptionAndBreakage
263000000 usd
us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
109000000 usd
us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
0 usd
cvs Contract With Customer Liability Other Increase Decrease
ContractWithCustomerLiabilityOtherIncreaseDecrease
4000000 usd
cvs Contract With Customer Liability Other Increase Decrease
ContractWithCustomerLiabilityOtherIncreaseDecrease
0 usd
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
167000000 usd
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
74000000 usd
CY2022Q3 us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
17401000000 usd
CY2022Q3 cvs Operating Expenses Excluding Goodwill Impairments Loss On Assets Held For Sale And Loss On Litigation Settlement
OperatingExpensesExcludingGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement
9612000000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
85078000000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3919000000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4444000000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1045000000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-3399000000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3406000000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.59
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.59
us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
52814000000 usd
cvs Operating Expenses Excluding Goodwill Impairments Loss On Assets Held For Sale And Loss On Litigation Settlement
OperatingExpensesExcludingGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement
28123000000 usd
us-gaap Costs And Expenses
CostsAndExpenses
234326000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
4295000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2686000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
691000000 usd
us-gaap Profit Loss
ProfitLoss
1995000000 usd
us-gaap Net Income Loss
NetIncomeLoss
1977000000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.49
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2636000000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
65633000000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
24803000000 usd
CY2022Q4 us-gaap Assets
Assets
228275000000 usd
CY2022Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
10142000000 usd
CY2022Q4 cvs Other Insurance Liabilities Current
OtherInsuranceLiabilitiesCurrent
1089000000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
69421000000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4016000000 usd
CY2022Q4 cvs Other Insurance Liabilities Noncurrent
OtherInsuranceLiabilitiesNoncurrent
5835000000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6730000000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
156506000000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
56398000000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1264000000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
71469000000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71769000000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
228275000000 usd
us-gaap Profit Loss
ProfitLoss
1995000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3181000000 usd
cvs Deferred Income Taxes And Other Noncash Items
DeferredIncomeTaxesAndOtherNoncashItems
-2213000000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
244000000 usd
us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
4476000000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
7371000000 usd
CY2023Q2 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
5000000000 usd
CY2023Q1 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
6000000000 usd
CY2023Q2 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
496000000 usd
CY2023Q2 us-gaap Severance Costs1
SeveranceCosts1
344000000 usd
CY2023Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
152000000 usd
CY2023Q3 us-gaap Severance Costs1
SeveranceCosts1
11000000 usd
CY2023Q3 us-gaap Payments For Postemployment Benefits
PaymentsForPostemploymentBenefits
58000000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
4515 security
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
6501000000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
234000000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
7900 security
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
11675000000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
1501000000 usd
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
3145000000 usd
CY2023Q3 cvs Long Term Investments Including Assets Held For Sale
LongTermInvestmentsIncludingAssetsHeldForSale
21667000000 usd
CY2023Q3 us-gaap Investments
Investments
24812000000 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
2778000000 usd
CY2022Q4 cvs Long Term Investments Including Assets Held For Sale
LongTermInvestmentsIncludingAssetsHeldForSale
21113000000 usd
CY2022Q4 us-gaap Investments
Investments
23891000000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
22102000000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
1000000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
22101000000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
35000000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1735000000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
20401000000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
22067000000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
4000000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
22063000000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
57000000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1840000000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
20280000000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
1273000000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1254000000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
7413000000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
6995000000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
4279000000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
3891000000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
4106000000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
3518000000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
22101000000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
20401000000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
12415 security
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
18176000000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1735000000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
9500 security
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
14228000000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1226000000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
2784 security
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
4264000000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
614000000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
12284 security
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
18492000000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1840000000 usd
CY2023Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear
1048000000 usd
CY2023Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss
20000000 usd
CY2023Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears
6507000000 usd
CY2023Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss
423000000 usd
CY2023Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears
3552000000 usd
CY2023Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss
395000000 usd
CY2023Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears
3310000000 usd
CY2023Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss
597000000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
18176000000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1735000000 usd
CY2023Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
432000000 usd
CY2022Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
322000000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1264000000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
827000000 usd
CY2023Q3 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
13000000 usd
CY2022Q3 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
11000000 usd
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
34000000 usd
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
29000000 usd
CY2023Q3 cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
419000000 usd
CY2022Q3 cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
311000000 usd
cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
1230000000 usd
cvs Investment Income Excluding Capital Gains Or Losses
InvestmentIncomeExcludingCapitalGainsOrLosses
798000000 usd
CY2023Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-142000000 usd
CY2022Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-110000000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-345000000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-283000000 usd
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
277000000 usd
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
201000000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
885000000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
515000000 usd
CY2023Q3 cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
47000000 usd
CY2023Q3 cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0 usd
cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
108000000 usd
cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
-3000000 usd
CY2022Q3 cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
73000000 usd
CY2022Q3 cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
1000000 usd
CY2023Q3 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1171000000 usd
CY2022Q3 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
593000000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
3503000000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
2000000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
3000000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
110000000 usd
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0 usd
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
42000000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
29000000 usd
us-gaap Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense
ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of the change in health care costs payable during the nine months ended September 30, 2023 and 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Impact of discount rate on long-duration insurance reserves </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,129 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,670 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Components of incurred health care costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(679)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred health care costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,504 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,546 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Claims paid</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,952 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,632 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,159 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Premium deficiency reserve</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,121 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Impact of discount rate on long-duration insurance reserves </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,550 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,131 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the difference between the current discount rate and the locked-in discount rate on long-duration insurance reserves which is recorded within accumulated other comprehensive loss on the unaudited condensed consolidated balance sheets. Refer to Note 1 ‘‘Significant Accounting Policies’’ for further information related to the adoption of the long-duration insurance contracts accounting standard. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Total incurred health care costs for the nine months ended September 30, 2023 and 2022 in the table above exclude $62 million and $59 million, respectively, of health care costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets and $163 million and $204 million, respectively, of health care costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets. The incurred health care costs for the nine months ended September 30, 2022 also exclude $5 million for a premium deficiency reserve related to the Company’s Medicaid products.</span></div>
CY2023Q3 us-gaap Shortduration Insurance Contracts Incurred But Not Reported Ibnr Claims Liability Net
ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet
8900000000 usd
CY2022Q4 us-gaap Policyholder Funds
PolicyholderFunds
345000000 usd
CY2021Q4 us-gaap Policyholder Funds
PolicyholderFunds
522000000 usd
cvs Policyholder Account Balance Deposits Received
PolicyholderAccountBalanceDepositsReceived
-1000000 usd
cvs Policyholder Account Balance Deposits Received
PolicyholderAccountBalanceDepositsReceived
-10000000 usd
us-gaap Policyholder Account Balance Policy Charge
PolicyholderAccountBalancePolicyCharge
2000000 usd
us-gaap Policyholder Account Balance Policy Charge
PolicyholderAccountBalancePolicyCharge
1000000 usd
us-gaap Policyholder Account Balance Surrender And Withdrawal
PolicyholderAccountBalanceSurrenderAndWithdrawal
23000000 usd
us-gaap Policyholder Account Balance Surrender And Withdrawal
PolicyholderAccountBalanceSurrenderAndWithdrawal
27000000 usd
us-gaap Interest Credited To Policyholders Account Balances
InterestCreditedToPolicyholdersAccountBalances
9000000 usd
us-gaap Interest Credited To Policyholders Account Balances
InterestCreditedToPolicyholdersAccountBalances
10000000 usd
cvs Policyholder Account Balance Change In Net Unrealized Gains Losses
PolicyholderAccountBalanceChangeInNetUnrealizedGainsLosses
-4000000 usd
cvs Policyholder Account Balance Change In Net Unrealized Gains Losses
PolicyholderAccountBalanceChangeInNetUnrealizedGainsLosses
-163000000 usd
us-gaap Policyholder Account Balance Increase Decrease From Other Change
PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange
-23000000 usd
us-gaap Policyholder Account Balance Increase Decrease From Other Change
PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange
-18000000 usd
CY2023Q3 us-gaap Policyholder Funds
PolicyholderFunds
303000000 usd
CY2022Q3 us-gaap Policyholder Funds
PolicyholderFunds
333000000 usd
CY2023Q3 us-gaap Policyholder Account Balance Weighted Average Crediting Rate
PolicyholderAccountBalanceWeightedAverageCreditingRate
0.0440
CY2022Q3 us-gaap Policyholder Account Balance Weighted Average Crediting Rate
PolicyholderAccountBalanceWeightedAverageCreditingRate
0.0480
CY2023Q3 us-gaap Policyholder Account Balance Net Amount At Risk
PolicyholderAccountBalanceNetAmountAtRisk
0 usd
CY2022Q3 us-gaap Policyholder Account Balance Net Amount At Risk
PolicyholderAccountBalanceNetAmountAtRisk
0 usd
CY2023Q3 us-gaap Cash Surrender Value Due Policyholders Amount
CashSurrenderValueDuePolicyholdersAmount
324000000 usd
CY2022Q3 us-gaap Cash Surrender Value Due Policyholders Amount
CashSurrenderValueDuePolicyholdersAmount
337000000 usd
CY2022Q4 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3228000000 usd
CY2021Q4 us-gaap Separate Accounts Liability
SeparateAccountsLiability
5087000000 usd
us-gaap Separate Account Liability Premium And Deposit
SeparateAccountLiabilityPremiumAndDeposit
657000000 usd
us-gaap Separate Account Liability Premium And Deposit
SeparateAccountLiabilityPremiumAndDeposit
636000000 usd
us-gaap Separate Account Liability Surrender And Withdrawal
SeparateAccountLiabilitySurrenderAndWithdrawal
7000000 usd
us-gaap Separate Account Liability Surrender And Withdrawal
SeparateAccountLiabilitySurrenderAndWithdrawal
576000000 usd
us-gaap Separate Account Liability Benefit Payment
SeparateAccountLiabilityBenefitPayment
714000000 usd
us-gaap Separate Account Liability Benefit Payment
SeparateAccountLiabilityBenefitPayment
711000000 usd
us-gaap Separate Account Liability Increase Decrease From Invested Performance
SeparateAccountLiabilityIncreaseDecreaseFromInvestedPerformance
42000000 usd
us-gaap Separate Account Liability Increase Decrease From Invested Performance
SeparateAccountLiabilityIncreaseDecreaseFromInvestedPerformance
-1057000000 usd
us-gaap Transfer To From Policyholder Account Balance To From Separate Account
TransferToFromPolicyholderAccountBalanceToFromSeparateAccount
-4000000 usd
us-gaap Transfer To From Policyholder Account Balance To From Separate Account
TransferToFromPolicyholderAccountBalanceToFromSeparateAccount
-7000000 usd
us-gaap Separate Account Liability Increase Decrease From Other Change
SeparateAccountLiabilityIncreaseDecreaseFromOtherChange
-10000000 usd
us-gaap Separate Account Liability Increase Decrease From Other Change
SeparateAccountLiabilityIncreaseDecreaseFromOtherChange
-68000000 usd
CY2023Q3 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3200000000 usd
CY2022Q3 us-gaap Separate Accounts Liability
SeparateAccountsLiability
3318000000 usd
CY2023Q3 us-gaap Separate Account Liability Cash Surrender Value Amount
SeparateAccountLiabilityCashSurrenderValueAmount
2136000000 usd
CY2022Q3 us-gaap Separate Account Liability Cash Surrender Value Amount
SeparateAccountLiabilityCashSurrenderValueAmount
2153000000 usd
CY2023Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
1493000000 usd
CY2022Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
1465000000 usd
CY2023Q3 cvs Short Term Debt Long Term Debt Gross And Lease Obligation
ShortTermDebtLongTermDebtGrossAndLeaseObligation
62479000000 usd
CY2022Q4 cvs Short Term Debt Long Term Debt Gross And Lease Obligation
ShortTermDebtLongTermDebtGrossAndLeaseObligation
52753000000 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
190000000 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
200000000 usd
CY2023Q3 cvs Debt Instrument Unamortized Discount And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet
755000000 usd
CY2022Q4 cvs Debt Instrument Unamortized Discount And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet
696000000 usd
CY2023Q3 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
61914000000 usd
CY2022Q4 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
52257000000 usd
CY2023Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
2132000000 usd
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1778000000 usd
CY2023Q3 cvs Long Term Debt And Lease Obligation Including Liabilities Held For Sale
LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale
59782000000 usd
CY2022Q4 cvs Long Term Debt And Lease Obligation Including Liabilities Held For Sale
LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale
50479000000 usd
CY2023Q2 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
4900000000 usd
CY2023Q1 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
6000000000 usd
CY2023Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.605
CY2022Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.55
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.815
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.65
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-146000000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-385000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
260000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1688000000 usd
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8000000 shares
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2261000000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
2261000000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3406000000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3406000000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
6298000000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6298000000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1977000000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
1977000000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1287000000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1315000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1284000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1313000000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1290000000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1315000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1289000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1324000000 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.76
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.90
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.51
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.75
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.49
CY2023Q3 cvs Guarantor Obligations Number Of Leases
GuarantorObligationsNumberOfLeases
63 lease
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 segment
CY2022Q3 us-gaap Revenues
Revenues
81159000000 usd
CY2022Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4349000000 usd
us-gaap Revenues
Revenues
238621000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13958000000 usd
CY2023Q3 cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
89487000000 usd
CY2023Q3 us-gaap Net Investment Income
NetInvestmentIncome
277000000 usd
CY2023Q3 us-gaap Revenues
Revenues
89764000000 usd
CY2023Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4456000000 usd
CY2022Q3 cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
80958000000 usd
CY2022Q3 us-gaap Net Investment Income
NetInvestmentIncome
201000000 usd
CY2022Q3 us-gaap Revenues
Revenues
81159000000 usd
CY2022Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4349000000 usd
cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
263078000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
885000000 usd
us-gaap Revenues
Revenues
263963000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13307000000 usd
cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
238106000000 usd
us-gaap Net Investment Income
NetInvestmentIncome
515000000 usd
us-gaap Revenues
Revenues
238621000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13958000000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3690000000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3919000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
10370000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
4295000000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
509000000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
458000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1396000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1380000000 usd
CY2023Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-142000000 usd
CY2022Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-110000000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-345000000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-283000000 usd
CY2023Q3 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
94000000 usd
CY2022Q3 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
0 usd
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
294000000 usd
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
0 usd
CY2023Q3 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
11000000 usd
CY2022Q3 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0 usd
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
507000000 usd
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0 usd
CY2023Q3 cvs Office Real Estate Optimization Charges
OfficeRealEstateOptimizationCharges
10000000 usd
CY2022Q3 cvs Office Real Estate Optimization Charges
OfficeRealEstateOptimizationCharges
0 usd
cvs Office Real Estate Optimization Charges
OfficeRealEstateOptimizationCharges
46000000 usd
cvs Office Real Estate Optimization Charges
OfficeRealEstateOptimizationCharges
0 usd
CY2023Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
CY2022Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
2480000000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
349000000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
2521000000 usd
CY2023Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
CY2022Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-5220000000 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-5704000000 usd
CY2023Q3 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
CY2022Q3 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
225000000 usd
CY2023Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4456000000 usd
CY2022Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4349000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13307000000 usd
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13958000000 usd
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
cvs-20230930_cal.xml Edgar Link unprocessable
cvs-20230930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0000064803-23-000047-index-headers.html Edgar Link pending
0000064803-23-000047-index.html Edgar Link pending
0000064803-23-000047.txt Edgar Link pending
0000064803-23-000047-xbrl.zip Edgar Link pending
a09302023ex101.htm Edgar Link pending
a09302023ex151.htm Edgar Link pending
a09302023ex311.htm Edgar Link pending
a09302023ex312.htm Edgar Link pending
a09302023ex321.htm Edgar Link pending
a09302023ex322.htm Edgar Link pending
cvs-20230930.htm Edgar Link pending
cvs-20230930.xsd Edgar Link pending
cvs-20230930_g1.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
cvs-20230930_htm.xml Edgar Link completed
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cvs-20230930_def.xml Edgar Link unprocessable
cvs-20230930_pre.xml Edgar Link unprocessable